Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
LAG3 expression
i
Other names:
LAG3, Lymphocyte Activating 3, Lymphocyte Activation Gene 3 Protein, Lymphocyte-Activation Gene 3, CD223 Antigen, CD223, LAG-3, FDC
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3902
Related biomarkers:
Expression
Mutation
Others
‹
LAG3 mutation (1)
LAG3 mutation (1)
›
Associations
(6)
News
Trials
Search handles
@jasonlukemd
@msaerens01
Search handles
@jasonlukemd
@msaerens01
Filter by
Latest
1year
Nivolumab & relatlimab demonstrated clinical benefit w/ a manageable safety profile in pts w/ advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression. @evanlipson @hopkinskimmel #melsm https://t.co/K7sJD0Bhlq (@OncLive)
1 year ago
Clinical • IO biomarker • Metastases
|
LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression • LAG3 expression
|
Opdivo (nivolumab) • relatlimab (BMS-986016)
1year
Nivolumab & relatlimab demonstrated clinical benefit w/ a manageable safety profile in pts w/ advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression. @evanlipson @hopkinskimmel #melsm https://t.co/yG5OlPCryK (@OncLive)
1 year ago
Clinical • IO biomarker • Metastases
|
LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression • LAG3 expression
|
Opdivo (nivolumab) • relatlimab (BMS-986016)
over1year
So proud of research team @MelanomaAus presenting at @SocietyMelanoma congress on spatial analysis and expression LAG3 in advanced #melanoma. @inespiresilva @ProfRScolyerMIA (@ProfGLongMIA)
over 1 year ago
IO biomarker
|
LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
2years
@DrChoueiri on translocation-associated RCC @bmuc_be : more LAG-3 expression >> therapeutic agent? (@msaerens01)
2 years ago
IO biomarker
|
LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
2years
Novel pred biomarkers of response to ICB w/ Nivo ± Ipi in TITAN-RCC ph 2 trial 📌Nivo induction: ⬆️ 4-1BB- or LAG-3 expressing T cells ➡️ Rx response 📌Nivo + Ipi “boosts”: ⬆️ PD-L1-expressing myeloid cells & plasmacytoid dendritic cell ➡️ better prog @urotoday #GU22 Rapid Abst (@zklaassen_md)
2 years ago
IO biomarker
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression • LAG3 expression
|
Opdivo (nivolumab)
2years
Could concomitant type 2 diabetes influence response to checkpoint inhibition in metastatic melanoma? A potential role for Lag-3 expression is reported in this Letter to the Editor by @PAscierto and coll. https://t.co/FoLSGve0SQ #melsm (@Annals_Oncology)
2 years ago
Checkpoint inhibition • IO biomarker
|
LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
3years
RELATIVITY-047 (Nivo + relatlimab anti-LAG3) is (+) for PFS #melanoma! 1st validated checkpoint beyond PD1/CTLA4. Can't wait to see breakdown by PDL1 & LAG3 expression. Where ipi-nivo works best in PDL1 lo, my guess is this works best in PDL1 hi. Biomarker time in #immunotherapy! (@jasonlukemd)
3 years ago
IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • LAG3 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login